Zai Lab $ZLAB (-0.78%) and Novocure $NVCR (-0.34%) Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

stat sig improvement in OS in unresectable, locally advanced PDAC treated with 1L TTFields concomitant with gem+nab-paclitaxel (not "clinically meaningfull"?)

mOS 16.2mo vs 14.16mo - OS HR =0.819 / p=0.039 /N=571 in ITT pop

curves seemingly stuck over first 12mo with larger separation during the 2nd year

$NVCR plans to file for regulatory approval in the US, EU, Japan and other key markets; $ZLAB plans to file for regulatory approval in China